Find a Research Expert

Experts
 Menu

John Crown

Institution

Dublin City University

Contact

Subjects

Biochemistry

Medicine & Nursing

Microbiology

Details
Publications 104
As first author 0
As last author 26
Unique topics 582
Collaborations 118
Patents 1
Sources 13
Are you John Crown? Click here to provide feedback on your profile.
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
Earlier

2019

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
2019

Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.
2019

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
2019

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and
2018

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
2018

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
2018

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
2018

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
2018

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
2018

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
2017

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
2017

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
2017

Mutant p53 as a target for cancer treatment.
2017

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
2017

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer
2017

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.
2017

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
2017

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
2017

Vitamin D receptor as a target for breast cancer therapy.
2016

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.
2016

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
2016

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
2016

Pre-clinical evaluation of the AR inhibitor enzalutamide in triple negative breast cancer cells.
2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
2016

The ADAMs Family of Proteases as Targets for the Treatment of Cancer.
2016

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
2016

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
2016

Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.
2016

Validated biomarkers: The key to precision treatment in patients with breast cancer.
2016

Vitamin D analogues: Potential use in cancer treatment.
2015

ADAM10: a new player in breast cancer progression?
2015

Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
2015

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
2015

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
2015

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
2015

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
2015

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
2014

ADAM10 and ADAM17: New players in trastuzumab tesistance.
2014

Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer.
2014

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
2014

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
2014

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.
2014

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
2014

Predictive biomarkers for dasatinib treatment in melanoma
2014

Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients.
2014

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
2013

A gene expression profile indicative of early stage HER2 targeted therapy response.
2013

Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer.
2013

Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.
2013

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
2013

Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
2013

Monitoring response to therapy in patients with cancer: is circulating DNA the answer?
2013

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
2013

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
2013

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
2012

Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer
2012

Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
2012

EGFR and HER2 inhibition in pancreatic cancer.
2012

Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells.
2012

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.
2012

Structure--activity relationship and mode of action of N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters: novel organometallic anticancer compounds.
2012

miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.
2011

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines
2011

Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.
2011

Analysis of gene expression as relevant to cancer cells and circulating tumour cells.
2011

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
2011

Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice.
2011

Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling.
2011

Src: a potential target for the treatment of triple-negative breast cancer.
2011

The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERĪ±, and is an independent prognostic factor in node-negative breast cancer.
2011

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
2011

Truncated HER2: implications for HER2-targeted therapeutics.
2010

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.
2010

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
2010

Intracellular and extracellular microRNAs in breast cancer.
2010

MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis.
2010

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
2010

Prospects for non-immunological molecular therapeutics in melanoma.
2010

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
2010

Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agents
2009

Alterations in integrin expression modulates invasion of pancreatic cancer cells
2009

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
2009

Expression of multidrug resistance markers ABCB1 (MDR-1/ Pgp) and ABCC1 (MRP-1) in renal cell carcinoma
2009

Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal carcinoma
2009

HER-2 signaling and inhibition in breast cancer.
2009

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer.
2009

TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer.
2009

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
2008

ADAM-17 predicts adverse outcome in patients with breast cancer.
2008

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
2007

2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins.
2007

Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue.
2007

EGFR and HER-2 antagonists in breast cancer.
2007

MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.
2007

Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
2006

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
2006

Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples.
2006

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
2005

Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-up.
2004

Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
2004

Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study.
2003

Caspase 3 in breast cancer.

These arethe13 unique sources for John Crown's 104 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 62
Ireland -> Dublin City University -> PubMed 59
Ireland -> Maynooth University 4
Ireland -> National University of Ireland Galway 1
Ireland -> National University of Ireland Galway -> PubMed 1
Ireland -> Royal College of Surgeons in Ireland 5
Ireland -> Royal College of Surgeons in Ireland -> PubMed 3
Ireland -> TU Dublin (Tallaght Campus) 1
Ireland -> TU Dublin (Tallaght Campus) -> PubMed 1
Ireland -> Trinity College Dublin 21
Ireland -> Trinity College Dublin -> PubMed 10
Ireland -> University College Dublin 18
Ireland -> University College Dublin -> PubMed 17
Mar 19, 2009

A METHOD OF ASSESSING CANCER STATUS IN AN INDIVIDUAL
+

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.